Scientists expect cure for cancer in 1 year

Grant Boone
January 30, 2019

A team of Israeli scientists believes a cure for cancer is within reach, even optimistically predicting that it will be found within a year.

"We believe we will offer in a year's time a complete cure for cancer", said Dan Aridor, chairman of the company's board, reported the Post. "The invention is based on an unexpected observation that a construct comprising two peptides binding two different targets on cancer cells and a toxin has an advantageous and, in some cases, a synergic cytotoxic effect in comparison to constructs having only one of these peptides".

Morad said that the company's technique "made sure that the treatment will not be affected by mutations; cancer cells can mutate in such a way that targeted receptors are dropped by the cancer ..."

That translates to about 2.6 million fewer cancer deaths total than would have been expected if death rates stayed at their peak, which was seen in 1991, according to the study.

Dr. Len Lichtenfeld, chief medical officer of the American Cancer Society, said in a blog Tuesday that "it goes without saying, we all share the aspirational hope that they are correct".

Morad said MuTato, because it attacks multiple targets, destroys the proteins targeted on the cancer cell.

Radical Revamp of Facebook Apps
Facebook has made recent headlines in the debate of user privacy and the collection of personal information. The integration will let them chat with their wider social network from any one of the three platforms.

"Our solution will be both generic and personal", Aridor stated. "Not even cancer can mutate three receptors at the same time".

Another reason why cancer drugs fail and the disease returns is because the drugs do not destroy cancer stem cells.

The company, however, has only tested the treatment in mice so far and it can take six to seven years to bring cancer drugs from "mouse to market", even when drugmakers receive special permissions from USA regulators to speed drug development, Les Funtleyder, health-care portfolio manager at E Squared Capital Management, told CNBC.

Morad told the Post that his team has concluded its first exploratory experiment on mice with promising results.

He also said the company was about to begin a round of clinical trials which would be completed within a few years.

Aridor says the team's treatment, which they have dubbed MuTaTo, is essentially a cancer antibiotic with an approach similar to the treatment given to AIDS patients.

Other reports by

Discuss This Article